AIMC Topic: SEER Program

Clear Filters Showing 91 to 100 of 106 articles

Development of Machine Learning Algorithms for Prediction of 5-Year Spinal Chordoma Survival.

World neurosurgery
BACKGROUND: Chordomas are locally invasive slow-growing tumors that are difficult to study because of the rarity of the tumors and the lack of significant volumes of patients with longitudinal follow-up. As such, there are currently no machine learni...

Breast cancer data analysis for survivability studies and prediction.

Computer methods and programs in biomedicine
BACKGROUND: Breast cancer is the most common cancer affecting females worldwide. Breast cancer survivability prediction is challenging and a complex research task. Existing approaches engage statistical methods or supervised machine learning to asses...

Characterizing Autoimmune Disease-associated Diffuse Large B-cell Lymphoma in a SEER-Medicare Cohort.

Clinical lymphoma, myeloma & leukemia
BACKGROUND: Severe immune dysregulation such as seen in autoimmune (AI) disease is known to act as a significant risk factor for diffuse large B-cell lymphoma (DLBCL). However, little is known about the demographics or clinical outcomes of DLBCL that...

Machine learning-based reconstruction of prognostic staging for gastric cancer patients with different differentiation grades: A multicenter retrospective study.

World journal of gastroenterology
BACKGROUND: The prognosis of gastric cancer (GC) patients is poor, and an accurate prognostic staging system would help assess patients' prognostic status before treatment and determine appropriate treatment strategies.

Epidemiology characteristics and clinical outcomes of composite Hodgkin lymphoma and diffuse large B-cell lymphoma using machine learning.

The oncologist
Composite lymphoma (CL) is rare. We conducted an analysis of 53 329 cases of diffuse large B-cell lymphoma (DLBCL), 17,916 cases of Hodgkin lymphoma (HL), and 869 cases of composite HL and DLBCL from the SEER database diagnosed between 2000 and 2019....

Determining health care cost drivers in older Hodgkin lymphoma survivors using interpretable machine learning methods.

Journal of managed care & specialty pharmacy
BACKGROUND: The cost of health care for patients with Hodgkin lymphoma (HL) is projected to rise, making it essential to understand expenditure drivers across different demographics, including the older adult population. Although older HL patients co...

Model development and validation for predicting small-cell lung cancer bone metastasis utilizing diverse machine learning algorithms based on the SEER database.

Medicine
The aim of this study was to devise a machine learning algorithm with superior performance in predicting bone metastasis (BM) in small cell lung cancer (SCLC) and create a straightforward web-based predictor based on the developed algorithm. Data com...

Ensemble learning guided survival prediction and chemotherapy benefit analysis in high-grade chondrosarcoma: A study based on the surveillance, epidemiology, and end results (SEER) database.

Journal of orthopaedic surgery (Hong Kong)
The chemotherapy benefit for high-grade chondrosarcoma remains controversial. Ensemble learning has better overall performance than single computational approaches for clinical decision. The primary objective was to select prognostic variables and d...

Machine learning-based individualized survival prediction model for prognosis in osteosarcoma: Data from the SEER database.

Medicine
Patient outcomes of osteosarcoma vary because of tumor heterogeneity and treatment strategies. This study aimed to compare the performance of multiple machine learning (ML) models with the traditional Cox proportional hazards (CoxPH) model in predict...

Leveraging SEER data through machine learning to predict distant lymph node metastasis and prognosticate outcomes in hepatocellular carcinoma patients.

The journal of gene medicine
OBJECTIVES: This study aims to develop and validate machine learning-based diagnostic and prognostic models to predict the risk of distant lymph node metastases (DLNM) in patients with hepatocellular carcinoma (HCC) and to evaluate the prognosis for ...